Abstract
In a prospective randomized, controlled trial in Uganda comparing the efficacy of antiretroviral therapy during tuberculosis therapy with the efficacy of tuberculosis therapy alone in HIV-infected patients with tuberculosis who have a CD4(+) cell count >350 cells/microL, it was found that antiretroviral therapy did not accelerate microbiologic, radiographic, or clinical responses to tuberculosis therapy: 18% of participants had sputum smears positive for Mycobacterium tuberculosis after 5 months of tuberculosis therapy, despite having had negative culture results. Trial registration. ClinicalTrials.gov identifier: NCT00078247 .
Publication types
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adult
-
Anti-HIV Agents / administration & dosage*
-
Antiretroviral Therapy, Highly Active / methods*
-
Antitubercular Agents / administration & dosage*
-
CD4 Lymphocyte Count
-
Female
-
HIV Infections / complications*
-
HIV Infections / drug therapy
-
HIV Infections / immunology
-
Humans
-
Lung / pathology
-
Male
-
Mycobacterium tuberculosis / isolation & purification
-
Prospective Studies
-
Radiography, Thoracic
-
Sputum / microbiology
-
Treatment Outcome
-
Tuberculosis / drug therapy*
-
Tuberculosis / microbiology
-
Tuberculosis / pathology
-
Uganda
Substances
-
Anti-HIV Agents
-
Antitubercular Agents
Associated data
-
ClinicalTrials.gov/NCT00078247